Holen Sie sich die Stockscreener-App
11.93
2.32%
0.27
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
(KALV) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Has $54,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Dimensional Fund Advisors LP Acquires 89,001 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of “Buy” by Analysts - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Wells Fargo & Company MN Has $171,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
MetLife Investment Management LLC Lowers Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 11 - marketscreener.com
Analyzing Ratios: KalVista Pharmaceuticals Inc (KALV)’s Financial Story Unveiled - DWinneX
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
JPMorgan Chase & Co. Decreases Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Should investors be concerned about KalVista Pharmaceuticals Inc (KALV)? - uspostnews.com
KalVista Pharmaceuticals Inc [KALV] Shares Jump Approximately 27.74% Over the Year - knoxdaily.com
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - BioSpace
KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com
Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Kalvista stock holds $19 target, Market Outperform rating - Investing.com
Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India
Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com
(KALV) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle
The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter
KalVista: Poised For Rare Disease Transformation - Seeking Alpha
Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News
KalVista licensing deal with Kaken - The Pharma Letter
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World
KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia
KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa
KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace
KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com
KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha
Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener
KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):